BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

415 related articles for article (PubMed ID: 29082853)

  • 21. Comprehensive cancer-gene panels can be used to estimate mutational load and predict clinical benefit to PD-1 blockade in clinical practice.
    Campesato LF; Barroso-Sousa R; Jimenez L; Correa BR; Sabbaga J; Hoff PM; Reis LF; Galante PA; Camargo AA
    Oncotarget; 2015 Oct; 6(33):34221-7. PubMed ID: 26439694
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tumor CDKN2A-Associated JAK2 Loss and Susceptibility to Immunotherapy Resistance.
    Horn S; Leonardelli S; Sucker A; Schadendorf D; Griewank KG; Paschen A
    J Natl Cancer Inst; 2018 Jun; 110(6):677-681. PubMed ID: 29917141
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Janus kinase 2 activation mechanisms revealed by analysis of suppressing mutations.
    Hammarén HM; Virtanen AT; Abraham BG; Peussa H; Hubbard SR; Silvennoinen O
    J Allergy Clin Immunol; 2019 Apr; 143(4):1549-1559.e6. PubMed ID: 30092288
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical applicability and cost of a 46-gene panel for genomic analysis of solid tumours: Retrospective validation and prospective audit in the UK National Health Service.
    Hamblin A; Wordsworth S; Fermont JM; Page S; Kaur K; Camps C; Kaisaki P; Gupta A; Talbot D; Middleton M; Henderson S; Cutts A; Vavoulis DV; Housby N; Tomlinson I; Taylor JC; Schuh A
    PLoS Med; 2017 Feb; 14(2):e1002230. PubMed ID: 28196074
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mutational profiling of non-small-cell lung cancer patients resistant to first-generation EGFR tyrosine kinase inhibitors using next generation sequencing.
    Jin Y; Shao Y; Shi X; Lou G; Zhang Y; Wu X; Tong X; Yu X
    Oncotarget; 2016 Sep; 7(38):61755-61763. PubMed ID: 27528220
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bias-Corrected Targeted Next-Generation Sequencing for Rapid, Multiplexed Detection of Actionable Alterations in Cell-Free DNA from Advanced Lung Cancer Patients.
    Paweletz CP; Sacher AG; Raymond CK; Alden RS; O'Connell A; Mach SL; Kuang Y; Gandhi L; Kirschmeier P; English JM; Lim LP; Jänne PA; Oxnard GR
    Clin Cancer Res; 2016 Feb; 22(4):915-22. PubMed ID: 26459174
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Genomic and transcriptional alterations in first-line chemotherapy exert a potentially unfavorable influence on subsequent immunotherapy in NSCLC.
    He Y; Chen L; Zhao L; Dang S; Liu G; Sasada S; Ma PC; van Zandwijk N; Rosell R; Popper HH; Wang H; Jiang M; Guo H; Liu X; Chen S; Zhang X; Xu M; Zhu B; Liu M; Zhou C
    Theranostics; 2021; 11(14):7092-7109. PubMed ID: 34093873
    [No Abstract]   [Full Text] [Related]  

  • 28. JAK-mutant myeloproliferative neoplasms.
    Levine RL
    Curr Top Microbiol Immunol; 2012; 355():119-33. PubMed ID: 21823028
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term Benefit of PD-L1 Blockade in Lung Cancer Associated with JAK3 Activation.
    Van Allen EM; Golay HG; Liu Y; Koyama S; Wong K; Taylor-Weiner A; Giannakis M; Harden M; Rojas-Rudilla V; Chevalier A; Thai T; Lydon C; Mach S; Avila AG; Wong JA; Rabin AR; Helmkamp J; Sholl L; Carter SL; Oxnard G; Janne P; Getz G; Lindeman N; Hammerman PS; Garraway LA; Hodi FS; Rodig SJ; Dranoff G; Wong KK; Barbie DA
    Cancer Immunol Res; 2015 Aug; 3(8):855-63. PubMed ID: 26014096
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Somatic mutations of JAK1 and JAK3 in acute leukemias and solid cancers.
    Jeong EG; Kim MS; Nam HK; Min CK; Lee S; Chung YJ; Yoo NJ; Lee SH
    Clin Cancer Res; 2008 Jun; 14(12):3716-21. PubMed ID: 18559588
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression.
    Awad MM; Oxnard GR; Jackman DM; Savukoski DO; Hall D; Shivdasani P; Heng JC; Dahlberg SE; Jänne PA; Verma S; Christensen J; Hammerman PS; Sholl LM
    J Clin Oncol; 2016 Mar; 34(7):721-30. PubMed ID: 26729443
    [TBL] [Abstract][Full Text] [Related]  

  • 32. TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.
    Pardanani A; Hood J; Lasho T; Levine RL; Martin MB; Noronha G; Finke C; Mak CC; Mesa R; Zhu H; Soll R; Gilliland DG; Tefferi A
    Leukemia; 2007 Aug; 21(8):1658-68. PubMed ID: 17541402
    [TBL] [Abstract][Full Text] [Related]  

  • 33. JAK2 variations and functions in lung adenocarcinoma.
    Xu Y; Jin J; Xu J; Shao YW; Fan Y
    Tumour Biol; 2017 Jun; 39(6):1010428317711140. PubMed ID: 28639892
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Next-generation sequencing of liquid-based cytology non-small cell lung cancer samples.
    Reynolds JP; Zhou Y; Jakubowski MA; Wang Z; Brainard JA; Klein RD; Farver CF; Almeida FA; Cheng YW
    Cancer Cytopathol; 2017 Mar; 125(3):178-187. PubMed ID: 28085233
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Genomic profiling of lung adenocarcinoma patients reveals therapeutic targets and confers clinical benefit when standard molecular testing is negative.
    Lim SM; Kim EY; Kim HR; Ali SM; Greenbowe JR; Shim HS; Chang H; Lim S; Paik S; Cho BC
    Oncotarget; 2016 Apr; 7(17):24172-8. PubMed ID: 26992220
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Budget impact analysis of comprehensive genomic profiling in patients with advanced non-small cell lung cancer.
    Signorovitch J; Zhou Z; Ryan J; Anhorn R; Chawla A
    J Med Econ; 2019 Feb; 22(2):140-150. PubMed ID: 30430885
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinicopathological differences exist between CALR- and JAK2-mutated myeloproliferative neoplasms despite a similar molecular landscape: data from targeted next-generation sequencing in the diagnostic laboratory.
    Agarwal R; Blombery P; McBean M; Jones K; Fellowes A; Doig K; Forsyth C; Westerman DA
    Ann Hematol; 2017 May; 96(5):725-732. PubMed ID: 28161773
    [TBL] [Abstract][Full Text] [Related]  

  • 38. WP1066, a novel JAK2 inhibitor, suppresses proliferation and induces apoptosis in erythroid human cells carrying the JAK2 V617F mutation.
    Verstovsek S; Manshouri T; Quintás-Cardama A; Harris D; Cortes J; Giles FJ; Kantarjian H; Priebe W; Estrov Z
    Clin Cancer Res; 2008 Feb; 14(3):788-96. PubMed ID: 18245540
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Janus kinase 3-activating mutations identified in natural killer/T-cell lymphoma.
    Koo GC; Tan SY; Tang T; Poon SL; Allen GE; Tan L; Chong SC; Ong WS; Tay K; Tao M; Quek R; Loong S; Yeoh KW; Yap SP; Lee KA; Lim LC; Tan D; Goh C; Cutcutache I; Yu W; Ng CC; Rajasegaran V; Heng HL; Gan A; Ong CK; Rozen S; Tan P; Teh BT; Lim ST
    Cancer Discov; 2012 Jul; 2(7):591-7. PubMed ID: 22705984
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PIK3CA mutations in non-small cell lung cancer (NSCLC): genetic heterogeneity, prognostic impact and incidence of prior malignancies.
    Scheffler M; Bos M; Gardizi M; König K; Michels S; Fassunke J; Heydt C; Künstlinger H; Ihle M; Ueckeroth F; Albus K; Serke M; Gerigk U; Schulte W; Töpelt K; Nogova L; Zander T; Engel-Riedel W; Stoelben E; Ko YD; Randerath W; Kaminsky B; Panse J; Becker C; Hellmich M; Merkelbach-Bruse S; Heukamp LC; Büttner R; Wolf J
    Oncotarget; 2015 Jan; 6(2):1315-26. PubMed ID: 25473901
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.